AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the present application.

IN THE CLAIMS:

1-18. (Canceled).

19. (Currently Amended) <u>An oligosaccharide</u> Oligosacharides having the formula

wherein A is H or a glycosidically $\beta1-3$ linked D-glucopyranosyl residue (Glc $\beta1-3$), R_1 is OH, R_2 is H and R_3 is OH, acylamido or -NH-acyl (i.e. monosaccharide 1 is Gle or GleNAcyl) or R_1 is H, R_2 is OH and R_3 is acetamido or -NHCOCH $_3$ (i.e. monosaccharide 1 is GalNAc); B is H, an α -L-fucosyl or an α -L-fucosyl analogue, and R_4 is OH, acetamido or -NHCOCH $_3$ (i.e. monosaccharide 2 is optionally

fucesylated Glc or GlcNAc), the curved line between the saccharide units indicating that the monosaccharide 1 is $\beta 1-4$ linked to monosaccharide 2 when B is linked to the position 3 of the monosaccharide 2, and the monosaccharide 1 is β 1-3 linked to monosaccharide 2 when B is linked to the position 4 of the monosaccharide 2, monosaccharide 1 is GalNAc only monosaccharide 2 is Glc, n is 1 to 100, with the proviso that there is always at least one α -fucosyl or α -fucosyl analogous group present in the molecule, and p and k are 0 or 1, and $1 \le m \le 1000$, X is a monosaccharide selected from the group consisting of Glc, or GalNAc, optionally in reduced GlcNAc, Gal form, oligosaccharide containing one or more of said monosaccharide units, the monosaccharide 2 being $\beta 1-3$ or $\beta 1-4$ linked to saccharide X, Y is a spacer or linking group capable of linking X to Z, and Z is a mono- or polyvalent carrier molecule.

- 20. (Currently Amended) The oligosaccharide oligosaccharides according to claim 19, wherein B is $\alpha-L$ -fucosyl.
- 21. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides according to claim 20, wherein monosaccharide 1 is Glc or GlcNAc.

- 22. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides according to claim 19, wherein m is 1 to 100, and n is 1 to 10.
- 23. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides according to claim 22, wherein m is 1 to 10.
- 24. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides according to claim 19, wherein they have the formula

wherein the symbols have the meanings given in connection with the formula I in claim 19, and wherein the monosaccharides 1 and 2 are independently Glc and GlcNAc, B is L-fucosyl, and X is Glc or GlcNAc or a β 1-3 or β 1-4 linked oligomer comprising up to 10 units of Glc and/or GlcNAc.

25. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides according to claim 19, wherein A is H and the monosaccharides 1 and 2 are independently Glc or GlcNAc, B is L-fucosyl, p and k = 0 and

n = m = 1, and X is Glc or GlcNAc or a β 1-3 or β 1-4 linked oligomer comprising up to 10 units of Glc and/or GlcNAc having the formula

26. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides according to claim 19 having the formula

 $\label{eq:GlcNAc} Glc/GlcNAc\beta1-4\,(Fuc\beta1-3)\,Glc/GlcNAc\,(\beta1-4Glc/GlcNAc)_{\,n'}$ wherein n' is the integer 1 to 8.

- 27. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides according to claim 26, wherein n' is the integer 1 to 6.
- 28. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides according to claim 19 having the formula

GlcNAcyl β 1-4 (Fuc α 1-3) GlcNAc (β 1-4GlcNAc)_{n'}

wherein n' is the integer 1 to 8 and acyl is an alkanoyl group which contains 8 to 24 carbon atoms and 1 to 3 double bonds.

- 30. (Currently Amended) A process for the preparation of <u>an</u> <u>oligosaccharides</u> having the formula

wherein A is H or a glycosidically $\beta 1-3$ linked D-glucopyranosyl residue (Glc $\beta 1-3$), R_1 is OH, R_2 is H and R_3 is OH, acylamido or

-NH-acyl (i.e. monosaccharide 1 is Gle or GleNAcyl) or R_1 is H, R_2 is OH and R_3 is acetamido or -NHCOCH₃ (i.e. monosaccharide 1 is GalNAc); B is H, an α -L-fucosyl or an α -L-fucosyl analogue, and R_4 is OH, acetamido or -NHCOCH₃ (i.e. monosaccharide 2 is optionally fucosylated Gle or GleNAc), the curved line between the saccharide units indicating that the monosaccharide 1 is β 1-4 linked to monosaccharide 2 when B is linked to the position 3 of the monosaccharide 2, and the monosaccharide 1 is β 1-3 linked to monosaccharide 2 when B is linked to the position 4 of the monosaccharide 2, monosaccharide 1 is GalNAc only when monosaccharide 2 is Glc, n is 1 to 100, with the proviso that there is always at least one α -fucosyl or α -fucosyl analogous group present in the molecule, and

i) p and k are 0 and m is 1, in which case X is H, an aglycon residue or a monosaccharide selected from the group consisting of Glc, GlcNAc, Gal or GalNAc, optionally in reduced form, or oligosaccharide containing one or more of said monosaccharide units, the monosaccharide 2 being β 1-2, β 1-3, β 1-4 or β 1-6 linked to saccharide X, with the proviso that X is not H when both monosaccharides 1 and 2 are GlcNAc, B is L-fucosyl and n is 1 or ii) p is 1, k is 0 or 1 and 1 \leq m \leq 1000, in which case X is a straight bond, or a mono- or oligosaccharide as defined under i), Y

is a spacer or linking group capable of linking the saccharide 2 or X to Z, and Z is a mono- or polyvalent carrier molecule, said process being characterized in that a compound of the formula I, wherein B is always H, is fucosylated with donor nucleotide sugar containing L-fucose, or an analogue thereof, in the presence of a fucosyl transferase enzyme, and the fucosylated saccharide so prepared is optionally recovered.

- 31. (Previously Presented) The process according to claim 30, wherein the fucosyltransferase is mammalian αl -3 or αl -3/4 fucosyltransferase.
- 32. (Previously Presented) The process according to claim 30 or 31, wherein a N-acetyl-chitooligosaccharide is used as the starting material.
- 33. (Previously Presented) The process according to claims 30 or 31, wherein the donor nucleotide sugar containing L-fucose is GDP-L-fucose.
- 34. (Previously Presented) The process according to claim 31, wherein the fucosyltransferase is human $\alpha 1\text{--}3$ fucosyltransferase or

Appl. No. 10/089,229

- $\alpha 1\text{--}3/4$ fucosyltransferase III-VII, IX or $\alpha 1\text{--}3/4$ fucosyltransferase of human milk.
- 35. (Previously Presented) The process according to any one of claims 30, 31 or 34, wherein it comprises the further step of reacting the product obtained with the formula I with β -N-acetyl-hexosaminidase.
- 36. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides of claim 19, wherein monosaccharide 1 residue I is Glc.
- 37. (Currently Amended) The <u>oligosaccharide</u> oligo saccharides of claim 19, wherein monosaccharide 1 $\frac{1}{1}$ is GlcNAcyl.
- 38. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides of claim 19, wherein monosaccharide $\frac{1}{1}$ residue $\frac{1}{1}$ is GalNAc.
- 39. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides of claim 19, wherein monosaccharide <u>2</u> residue II is <u>optionally</u> fucosylated Glc.

Appl. No. 10/089,229

- 40. (Currently Amended) The <u>oligosaccharide</u> oligosaccharides of claim 19, wherein monosaccharide $\underline{2}$ residue II is optionally fucosylated GlcNAc.
- 41. (New) The process according to claim 30, wherein monosaccharide 1 is Glc.
- 42. (New) The process according to claim 30, wherein monosaccharide 1 is GlcNAcyl.
- 43. (New) The process according to claim 30, wherein monosaccharide 1 is GalNAc.
- 44. (New) The process according to claim 30, wherein monosaccharide 2 is optionally fucosylated Glc.
- 45. (New) The process according to claim 30, wherein monosaccharide 2 is optionally fucosylated GlcNAc.